Immuneering Corp (IMRX)
1.81
-0.13
(-6.70%)
USD |
NASDAQ |
Nov 15, 16:00
1.81
0.00 (0.00%)
After-Hours: 17:29
Immuneering Research and Development Expense (Quarterly): 10.65M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 10.65M |
| March 31, 2024 | 11.20M |
| December 31, 2023 | 11.91M |
| September 30, 2023 | 10.05M |
| June 30, 2023 | 9.453M |
| March 31, 2023 | 10.21M |
| December 31, 2022 | 9.872M |
| September 30, 2022 | 9.364M |
| June 30, 2022 | 7.981M |
| Date | Value |
|---|---|
| March 31, 2022 | 9.058M |
| December 31, 2021 | 7.950M |
| September 30, 2021 | 6.208M |
| June 30, 2021 | 6.992M |
| March 31, 2021 | 5.391M |
| December 31, 2020 | 4.890M |
| September 30, 2020 | 4.069M |
| June 30, 2020 | 3.221M |
| March 31, 2020 | 2.823M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.823M
Minimum
Mar 2020
11.91M
Maximum
Dec 2023
7.850M
Average
8.520M
Median
Research and Development Expense (Quarterly) Benchmarks
| Singular Genomics Systems Inc | 10.73M |
| Biomarin Pharmaceutical Inc | 184.90M |
| Integra Lifesciences Holdings Corp | 27.44M |
| Eton Pharmaceuticals Inc | 2.97M |
| Tenon Medical Inc | 0.708M |